Charles F. Wagner, Jr. Sells 343 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) CFO Charles F. Wagner, Jr. sold 343 shares of the stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $258.83, for a total transaction of $88,778.69. Following the completion of the sale, the chief financial officer now owns 42,730 shares of the company’s stock, valued at approximately $11,059,805.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

NASDAQ:VRTX opened at $273.70 on Thursday. Vertex Pharmaceuticals Incorporated has a 1 year low of $176.36 and a 1 year high of $292.75. The firm’s fifty day simple moving average is $259.65 and its 200 day simple moving average is $228.62. The company has a current ratio of 4.46, a quick ratio of 4.30 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $69.94 billion, a PE ratio of 30.31, a PEG ratio of 1.87 and a beta of 0.55.

A number of large investors have recently bought and sold shares of VRTX. Concord Wealth Partners grew its stake in Vertex Pharmaceuticals by 750.0% in the 4th quarter. Concord Wealth Partners now owns 119 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 105 shares during the last quarter. First PREMIER Bank acquired a new position in Vertex Pharmaceuticals in the 4th quarter valued at $27,000. Hudock Inc. grew its stake in Vertex Pharmaceuticals by 156.3% in the 3rd quarter. Hudock Inc. now owns 164 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 100 shares during the last quarter. Moors & Cabot Inc. acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $29,000. Finally, JJJ Advisors Inc. grew its stake in Vertex Pharmaceuticals by 101.5% in the 4th quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 67 shares during the last quarter. Institutional investors and hedge funds own 89.84% of the company’s stock.

A number of research firms have issued reports on VRTX. UBS Group increased their target price on shares of Vertex Pharmaceuticals from $258.00 to $325.00 in a research report on Wednesday, April 13th. Stifel Nicolaus increased their target price on shares of Vertex Pharmaceuticals from $213.00 to $222.00 and gave the stock a “hold” rating in a research report on Thursday, January 27th. Oppenheimer increased their target price on shares of Vertex Pharmaceuticals from $305.00 to $350.00 in a research report on Monday, April 4th. JPMorgan Chase & Co. increased their target price on shares of Vertex Pharmaceuticals from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Thursday, January 27th. Finally, Morgan Stanley upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $250.00 target price for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $273.43.

Vertex Pharmaceuticals Company Profile (Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

See Also